Washington University School of Medicine
St Louis, Missouri, 63110, United States
NCT Number: NCT02311556
This study is designed to evaluate whether advanced magnetic resonance imaging (MRI) techniques such as dynamic susceptibility-weighted contrast-enhanced perfusion MRI may be used to predict treatment response of brain metastasis after radiosurgery.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Phase 1
St Louis, Missouri, 63110, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Other names: DSC-PMR
Time frame: At time of radiosurgery and after radiosurgery (approximately 1 week)
Tumor perfusion on DSC-PMR will be used as predictor for time to local tumor progression.
Time frame: Up to 1 year
Radiation necrosis will be defined by pathology, when available. When no pathology is available, clinical diagnosis based on clinical course and management will be used.
Time frame: Up to 1 year
Complete response = no residue enhancing lesion on MRI
Time frame: Up to 1 year
Elsewhere brain failure = appearance of brain metastases outside of the prior radiosurgery region which can be diagnosed radiographically and does not required require pathological confirmation.
Time frame: Up to 1 year
Clinical deterioration will be assessed based on the Karnofsky Performance scale (KPS).
Washington University School of Medicine
Other
Assessment of Early Treatment Response of Brain Metastases After Gamma-Knife Radiosurgery Using Dynamic Susceptibility-weighted Contrast-enhanced Perfusion Magnetic Resonance Imaging
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07716124
Brain Diseases, Brain Metastases
Ljubljana, Slovenia
View Trial DetailsNCT04890028
Brain Diseases, Brain Metastases
Angers, France
View Trial DetailsNCT04545814
Brain Diseases, Brain Metastases
Milwaukee, Wisconsin, United States
View Trial DetailsNCT03714243
Brain Diseases, Brain Metastases
Toronto, Ontario, Canada
View Trial Details